Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NO or no NO in asthma?

P J Barnes1

  • 1Department of Thoracic Medicine, National Heart and Lung Institute, London, UK.

Thorax
|February 1, 1996
PubMed
Summary

Nitric oxide (NO) is elevated in asthma, acting as both a bronchodilator and an inflammatory mediator. Inhibiting inducible nitric oxide synthase (iNOS) may offer therapeutic benefits for asthma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995

Area of Science:

  • Respiratory Medicine
  • Molecular Biology
  • Immunology

Background:

  • Nitric oxide (NO) is a crucial molecule in the airways, functioning as a vasodilator, neurotransmitter, and inflammatory mediator.
  • Elevated NO levels are observed in asthma, suggesting a complex role in the disease pathophysiology.
  • NO can exert both beneficial (bronchodilation) and detrimental (increased plasma exudation, amplified inflammation) effects in the airways.

Purpose of the Study:

  • To explore the dual role of nitric oxide (NO) in asthma.
  • To investigate the source and regulation of increased NO production in asthmatic airways.
  • To evaluate the therapeutic potential of targeting NO pathways in asthma management.

Main Methods:

  • The study discusses the known roles of NO and its synthesis pathway, inducible nitric oxide synthase (iNOS).
  • It highlights the upregulation of iNOS in airway epithelial cells by proinflammatory cytokines and oxidants in asthma.
  • The text references the inhibition of iNOS by glucocorticoids and the potential of selective iNOS inhibitors.

Main Results:

  • Increased nitric oxide (NO) is a characteristic feature of asthma.
  • Inducible nitric oxide synthase (iNOS) expression is upregulated in asthmatic airway epithelial cells.
  • NO's role in asthma involves bronchodilation, vasodilation, and inflammatory modulation.

Conclusions:

  • Nitric oxide (NO) has a multifaceted role in asthma, contributing to both airway function and inflammation.
  • The increased production of NO in asthma is linked to the induction of iNOS.
  • Targeting iNOS with selective inhibitors presents a potential therapeutic strategy for managing asthma.

Related Experiment Videos